PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)

Giovanni Tomasello, Vincenzo Davide Palumbo, Attilio Ignazio Lo Monte, Francesco Cappello, Alida Abruzzo, Angelo Maria Patti, Provvidenza Damiani, Emanuele Sinagra, Maurizio Filippo Accardo, Marcello Noto, Rosaria Maria Giglio, Antonio Bruno, Giovanni Tomasello, Vincenzo Davide Palumbo, Francesco Cappello

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

Summary: This work reports a clinical trial performed at palermo University Hospital "paolo Giaccone". From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine (800 mg gastro-resistant tabletes, one tablet twice a day in mild forms, and one tablet three times per day in moderate forms). In group B, in addition to the previous treatment protocol, two probiotic mixture were added in a time of two weeks: in the first week, twice a day, one capsule containing mixture of Enterococcus faecium and saccharomices boluard was administered, with the main purpose to mitigate the intestinal inflammation; in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the main purpose to mitigate the intestinal inflammation, in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the aim to promote the restoration of a normal intestinal microenvironment. The attenuation of intestinal inflammation, improved by the presence of probiotics, could have important effects on the articular manifestations, resulting in a significant improvement of the arthropathy. All patients were evaluated with the Harvey-Bradshaw Index. Both Crohn Disease and Ulcerative Cholitis diagnosis was made with clinical, laboratory, endoscopic and instrumental tests; the degree of disease activity was evaluated using the criteria of Truelove and witts. The WOMAC-Score (Western Ontario Mcmaster) was used in our study to investigate the degree of articular involvement of the patients. The data were statistically evaluated and these are shown that the B group of patients treated with conventional therapy + probiotic mixture had a better resolution of the clinical and of this post-treatment parameters: WOMAC score, ESR, CRP and white blood cells; and also the B group of patients have a better response to standard therapy compared with patients who did not receive the probiotic with a remarkable statistic significance (p>0,0001).
Lingua originaleEnglish
pagine (da-a)176-187
Numero di pagine12
RivistaProgress in Nutrition
Volume16
Stato di pubblicazionePublished - 2014

Fingerprint

inflammatory bowel disease
Inflammatory Bowel Diseases
Probiotics
probiotics
Lactobacillus salivarius
Capsules
Lactobacillus acidophilus
Joint Diseases
Joints
inflammation
orthopedics
Inflammation
therapeutics
Tablets
Orthopedics
Therapeutics
Mesalamine
Enterococcus faecium
Crohn disease
Diclofenac

All Science Journal Classification (ASJC) codes

  • Food Science
  • Nutrition and Dietetics

Cita questo

PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD). / Tomasello, Giovanni; Palumbo, Vincenzo Davide; Lo Monte, Attilio Ignazio; Cappello, Francesco; Abruzzo, Alida; Patti, Angelo Maria; Damiani, Provvidenza; Sinagra, Emanuele; Accardo, Maurizio Filippo; Noto, Marcello; Giglio, Rosaria Maria; Bruno, Antonio; Tomasello, Giovanni; Palumbo, Vincenzo Davide; Cappello, Francesco.

In: Progress in Nutrition, Vol. 16, 2014, pag. 176-187.

Risultato della ricerca: Article

Tomasello, G, Palumbo, VD, Lo Monte, AI, Cappello, F, Abruzzo, A, Patti, AM, Damiani, P, Sinagra, E, Accardo, MF, Noto, M, Giglio, RM, Bruno, A, Tomasello, G, Palumbo, VD & Cappello, F 2014, 'PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)', Progress in Nutrition, vol. 16, pagg. 176-187.
Tomasello, Giovanni ; Palumbo, Vincenzo Davide ; Lo Monte, Attilio Ignazio ; Cappello, Francesco ; Abruzzo, Alida ; Patti, Angelo Maria ; Damiani, Provvidenza ; Sinagra, Emanuele ; Accardo, Maurizio Filippo ; Noto, Marcello ; Giglio, Rosaria Maria ; Bruno, Antonio ; Tomasello, Giovanni ; Palumbo, Vincenzo Davide ; Cappello, Francesco. / PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD). In: Progress in Nutrition. 2014 ; Vol. 16. pagg. 176-187.
@article{81c1bede44ba41f8909df4e3f8e5a7da,
title = "PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)",
abstract = "Summary: This work reports a clinical trial performed at palermo University Hospital {"}paolo Giaccone{"}. From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine (800 mg gastro-resistant tabletes, one tablet twice a day in mild forms, and one tablet three times per day in moderate forms). In group B, in addition to the previous treatment protocol, two probiotic mixture were added in a time of two weeks: in the first week, twice a day, one capsule containing mixture of Enterococcus faecium and saccharomices boluard was administered, with the main purpose to mitigate the intestinal inflammation; in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the main purpose to mitigate the intestinal inflammation, in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the aim to promote the restoration of a normal intestinal microenvironment. The attenuation of intestinal inflammation, improved by the presence of probiotics, could have important effects on the articular manifestations, resulting in a significant improvement of the arthropathy. All patients were evaluated with the Harvey-Bradshaw Index. Both Crohn Disease and Ulcerative Cholitis diagnosis was made with clinical, laboratory, endoscopic and instrumental tests; the degree of disease activity was evaluated using the criteria of Truelove and witts. The WOMAC-Score (Western Ontario Mcmaster) was used in our study to investigate the degree of articular involvement of the patients. The data were statistically evaluated and these are shown that the B group of patients treated with conventional therapy + probiotic mixture had a better resolution of the clinical and of this post-treatment parameters: WOMAC score, ESR, CRP and white blood cells; and also the B group of patients have a better response to standard therapy compared with patients who did not receive the probiotic with a remarkable statistic significance (p>0,0001).",
author = "Giovanni Tomasello and Palumbo, {Vincenzo Davide} and {Lo Monte}, {Attilio Ignazio} and Francesco Cappello and Alida Abruzzo and Patti, {Angelo Maria} and Provvidenza Damiani and Emanuele Sinagra and Accardo, {Maurizio Filippo} and Marcello Noto and Giglio, {Rosaria Maria} and Antonio Bruno and Giovanni Tomasello and Palumbo, {Vincenzo Davide} and Francesco Cappello",
year = "2014",
language = "English",
volume = "16",
pages = "176--187",
journal = "Progress in Nutrition",
issn = "1129-8723",
publisher = "Mattioli 1885 S.p.A.",

}

TY - JOUR

T1 - PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD)

AU - Tomasello, Giovanni

AU - Palumbo, Vincenzo Davide

AU - Lo Monte, Attilio Ignazio

AU - Cappello, Francesco

AU - Abruzzo, Alida

AU - Patti, Angelo Maria

AU - Damiani, Provvidenza

AU - Sinagra, Emanuele

AU - Accardo, Maurizio Filippo

AU - Noto, Marcello

AU - Giglio, Rosaria Maria

AU - Bruno, Antonio

AU - Tomasello, Giovanni

AU - Palumbo, Vincenzo Davide

AU - Cappello, Francesco

PY - 2014

Y1 - 2014

N2 - Summary: This work reports a clinical trial performed at palermo University Hospital "paolo Giaccone". From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine (800 mg gastro-resistant tabletes, one tablet twice a day in mild forms, and one tablet three times per day in moderate forms). In group B, in addition to the previous treatment protocol, two probiotic mixture were added in a time of two weeks: in the first week, twice a day, one capsule containing mixture of Enterococcus faecium and saccharomices boluard was administered, with the main purpose to mitigate the intestinal inflammation; in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the main purpose to mitigate the intestinal inflammation, in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the aim to promote the restoration of a normal intestinal microenvironment. The attenuation of intestinal inflammation, improved by the presence of probiotics, could have important effects on the articular manifestations, resulting in a significant improvement of the arthropathy. All patients were evaluated with the Harvey-Bradshaw Index. Both Crohn Disease and Ulcerative Cholitis diagnosis was made with clinical, laboratory, endoscopic and instrumental tests; the degree of disease activity was evaluated using the criteria of Truelove and witts. The WOMAC-Score (Western Ontario Mcmaster) was used in our study to investigate the degree of articular involvement of the patients. The data were statistically evaluated and these are shown that the B group of patients treated with conventional therapy + probiotic mixture had a better resolution of the clinical and of this post-treatment parameters: WOMAC score, ESR, CRP and white blood cells; and also the B group of patients have a better response to standard therapy compared with patients who did not receive the probiotic with a remarkable statistic significance (p>0,0001).

AB - Summary: This work reports a clinical trial performed at palermo University Hospital "paolo Giaccone". From January 2004 to December 2011, 79 patients were enrolled (40 men and 39 women). All patients suffered from Inflammatory Bowel Disease (IBD) and were subjected to orthopedic consultation at the institute of Orthopaedics, University Hospital of palermo, for arthropathy to IBD. The patients were divided into two groups (A and B) and dealt with different therapies for the resolution of the inflammatory picture of the colonic mucosa and the treatment of the extraintestinal articular manifestations. Group A was treated with drug therapy: Diclofenac (75 mg im/ day for 10 days9 and Mesalazine (800 mg gastro-resistant tabletes, one tablet twice a day in mild forms, and one tablet three times per day in moderate forms). In group B, in addition to the previous treatment protocol, two probiotic mixture were added in a time of two weeks: in the first week, twice a day, one capsule containing mixture of Enterococcus faecium and saccharomices boluard was administered, with the main purpose to mitigate the intestinal inflammation; in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the main purpose to mitigate the intestinal inflammation, in the second week, twice a day too, one capsule containing a mixture of lactobacillus salivarius and lactobacillus acidophilus was administered, with the aim to promote the restoration of a normal intestinal microenvironment. The attenuation of intestinal inflammation, improved by the presence of probiotics, could have important effects on the articular manifestations, resulting in a significant improvement of the arthropathy. All patients were evaluated with the Harvey-Bradshaw Index. Both Crohn Disease and Ulcerative Cholitis diagnosis was made with clinical, laboratory, endoscopic and instrumental tests; the degree of disease activity was evaluated using the criteria of Truelove and witts. The WOMAC-Score (Western Ontario Mcmaster) was used in our study to investigate the degree of articular involvement of the patients. The data were statistically evaluated and these are shown that the B group of patients treated with conventional therapy + probiotic mixture had a better resolution of the clinical and of this post-treatment parameters: WOMAC score, ESR, CRP and white blood cells; and also the B group of patients have a better response to standard therapy compared with patients who did not receive the probiotic with a remarkable statistic significance (p>0,0001).

UR - http://hdl.handle.net/10447/100972

M3 - Article

VL - 16

SP - 176

EP - 187

JO - Progress in Nutrition

JF - Progress in Nutrition

SN - 1129-8723

ER -